The risk of death after severe DOAC-related bleeding remains significant despite a high rate of effective haemostasis with reversal agents. That’s the conclusion from a systematic review and meta-analysis of the evidence for clinical outcomes following bleeding and use of 4-factor prothrombin complex concentrates (4PCC) or specific reversal agents idarucizumab and andexanet alfa. The meta-analysis, ...
DOAC reversal agents work but what comes next needs more data
By Mardi Chapman
12 Jul 2021